Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corp. (not Niagen Bioscience, Inc.) on October 18, 2013, reporting events occurring on October 17 and 18, 2013. The company is a Delaware corporation focused on developing novel nutritional ingredients.
Key Financial Metrics
The filing details two unregistered equity sales under Rule 506 of Regulation D:
- October 17 Transaction: Sold 2,941,176 shares at $0.85 per share for gross proceeds of $2,500,000.
- October 18 Transaction: Sold 588,235 shares at $0.85 per share for gross proceeds of $500,000.
- Total Gross Proceeds: $3,000,000.
- Placement Fee: $20,000 paid in connection with the October 18 transaction.
The filing text does not provide clear values for revenue, profit, operating cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the increase in equity capital through the issuance of 3,529,411 total shares of common stock to strategic accredited investors. The filing does not provide comparative financial data to assess changes versus prior periods.
Guidance, Outlook, and Risks
Use of Proceeds: Funds from the October 17 sale are designated for the further development of novel nutritional ingredients. Funds from the October 18 sale are for general working capital purposes.
Risks and Contingencies: The shares issued are restricted securities under Rule 144. The offering relied on exemptions from registration, meaning no general solicitation was conducted.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance to assess dilution impact.
- Confirm the identity of the "strategic accredited investors" and any related party relationships.
- Review the specific "novel nutritional ingredients" being developed to validate the use of proceeds.
- Check subsequent filings for the actual cash burn rate and remaining working capital runway.